Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 129
Filter
1.
Nature ; 537(7619): 185-190, 2016 09 08.
Article in English | MEDLINE | ID: mdl-27533032

ABSTRACT

Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by µ-opioid-receptor (µOR) signalling through the ß-arrestin pathway or by actions at other receptors. Conversely, G-protein µOR signalling is thought to confer analgesia. Here we computationally dock over 3 million molecules against the µOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for µOR and minimal ß-arrestin-2 recruitment. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. PZM21 thus serves as both a probe to disentangle µOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.


Subject(s)
Analgesics, Opioid/adverse effects , Analgesics, Opioid/chemistry , Drug Discovery , Receptors, Opioid, mu/agonists , Thiophenes/chemistry , Thiophenes/pharmacology , Urea/analogs & derivatives , Analgesia/methods , Analgesics, Opioid/pharmacology , Animals , GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , HEK293 Cells , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Molecular Docking Simulation , Pain/drug therapy , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/metabolism , Spiro Compounds/pharmacology , Structure-Activity Relationship , Thiophenes/adverse effects , Urea/adverse effects , Urea/chemistry , Urea/pharmacology
2.
Cell Mol Neurobiol ; 41(5): 1031-1038, 2021 Jul.
Article in English | MEDLINE | ID: mdl-32989585

ABSTRACT

Opioids, like morphine and naloxone, regulate the proliferation and neuronal differentiation of neural stem cells (NSCs) in a receptor-independent and ten-eleven translocation methylcytosine dioxygenase (TET1)-dependent manner in vitro. Whether naloxone regulates hippocampal NSCs and contextual learning in vivo in a similar manner was determined. Naloxone infusion increased the Ki67 and Doublecortin positive cells in subgranular zone of wild type mice, which suggested the increased proliferation and differentiation of hippocampal NSCs in vivo and was consistent with the in vitro functions of naloxone. In addition, naloxone infusion also facilitated the contextual learning and memory of wild type mice. To determine the contribution of µ-opioid receptor (OPRM1) and TET1 to these functions of naloxone, several types of knockout mice were used. Since Tet1-/- mice have high deficiency in contextual learning and memory, Tet1+/- mice were used instead. The abilities of naloxone to regulate NSCs and to facilitate contextual learning were significantly impaired in Tet1+/- mice. In addition, these abilities of naloxone were not affected in Oprm1-/- mice. Therefore, naloxone facilitates contextual learning and memory in a receptor-independent and Tet1-dependent manner, which provides new understanding on the receptor-independent functions of opioids.


Subject(s)
DNA-Binding Proteins/deficiency , Maze Learning/physiology , Memory/physiology , Naloxone/pharmacology , Narcotic Antagonists/pharmacology , Proto-Oncogene Proteins/deficiency , Receptors, Opioid, mu/deficiency , Animals , Cells, Cultured , DNA-Binding Proteins/genetics , Hippocampus/cytology , Hippocampus/drug effects , Hippocampus/metabolism , Male , Maze Learning/drug effects , Memory/drug effects , Mice , Mice, Knockout , Neural Stem Cells/drug effects , Neural Stem Cells/metabolism , Proto-Oncogene Proteins/genetics , Receptors, Opioid, mu/genetics
3.
J Neurosci Res ; 98(8): 1532-1548, 2020 08.
Article in English | MEDLINE | ID: mdl-32424971

ABSTRACT

Restless legs syndrome (RLS) is characterized by an irresistible need to move the legs while sitting or lying at night with insomnia as a frequent consequence. Human RLS has been associated with abnormalities in the endogenous opioid system, the dopaminergic system, the iron regulatory system, anemia, and inflammatory and auto-immune disorders. Our previous work indicates that mice lacking all three subtypes of opioid receptors have a phenotype similar to that of human RLS. To study the roles of each opioid receptor subtype in RLS, we first used mu opioid receptor knockout (MOR KO) mice based on our earlier studies using postmortem brain and cell culture. The KO mice showed decreased hemoglobin, hematocrit, and red blood cells (RBCs), with an appearance of microcytic RBCs indicating anemia. Together with decreased serum iron and transferrin, but increased ferritin levels, the anemia is similar to that seen with chronic inflammation in humans. A decreased serum iron level was also observed in the wildtype mice treated with an MOR antagonist. Iron was increased in the liver and spleen of the KO mice. Normal circadian variations in the dopaminergic and serotoninergic systems were absent in the KO mice. The KO mice showed hyperactivity and increased thermal sensitivity in wakefulness primarily during what would normally be the sleep phase similar to that seen in human RLS. Deficits in endogenous opioid system transmission could predispose to anemia of inflammation and loss of circadian variations in dopaminergic or serotonergic systems, thereby contributing to an RLS-like phenotype.


Subject(s)
Receptors, Opioid, mu/deficiency , Restless Legs Syndrome/blood , Restless Legs Syndrome/genetics , Anemia , Animals , Biogenic Monoamines/blood , Circadian Rhythm , Corpus Striatum , Dopamine/metabolism , Erythrocytes , Iron/blood , Mice , Mice, Knockout , Motor Activity , Pain , Psychomotor Agitation
4.
Proc Natl Acad Sci U S A ; 113(13): 3663-8, 2016 Mar 29.
Article in English | MEDLINE | ID: mdl-26976581

ABSTRACT

The clinical management of severe pain depends heavily on opioids acting through mu opioid receptors encoded by the Oprm1 gene, which undergoes extensive alternative splicing. In addition to generating a series of prototypic seven transmembrane domain (7TM) G protein-coupled receptors (GPCRs), Oprm1 also produces a set of truncated splice variants containing only six transmembrane domains (6TM) through which selected opioids such as IBNtxA (3'-iodobenzoyl-6ß-naltrexamide) mediate a potent analgesia without many undesirable effects. Although morphine analgesia is independent of these 6TM mu receptor isoforms, we now show that the selective loss of the 6TM variants in a knockout model eliminates the analgesic actions of delta and kappa opioids and of α2-adrenergic compounds, but not cannabinoid, neurotensin, or muscarinic drugs. These observations were confirmed by using antisense paradigms. Despite their role in analgesia, loss of the 6TM variants were not involved with delta opioid-induced seizure activity, aversion to the kappa drug U50, 488H, or α2-mediated hypolocomotion. These observations support the existence of parallel opioid and nonopioid pain modulatory systems and highlight the ability to dissociate unwanted delta, kappa1, and α2 actions from analgesia.


Subject(s)
Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/physiology , Alternative Splicing , Analgesia , Analgesics, Opioid/pharmacology , Animals , Female , Humans , Male , Mice , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Knockout , Morphine/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Pain Management , Pain Measurement , Protein Isoforms/deficiency , Protein Isoforms/genetics , Protein Isoforms/physiology , Protein Structure, Tertiary , Receptors, Opioid, mu/deficiency
5.
Mol Pain ; 14: 1744806917754142, 2018.
Article in English | MEDLINE | ID: mdl-29353538

ABSTRACT

Background Lithium is widely used to treat bipolar disorders and displays mood stabilizing properties. In addition, lithium relieves painful cluster headaches and has a strong analgesic effect in neuropathic pain rat models. Objectives To investigate the analgesic effect of lithium on the cuff model of neuropathic pain. Methods We used behavioral and pharmacological approaches to study the analgesic effect of a single injection of lithium in wild-type and mu opioid receptor (MOR) null cuffed neuropathic mice. Mass spectrometry and enzyme-linked immunosorbent assay allowed to measure the levels of endogenous MOR agonist beta-endorphin as well as monoamines in brain and plasma samples 4 h after lithium administration. Results A single injection of lithium chloride (100 mg/kg, ip) alleviated mechanical allodynia for 24 h, and this effect was absent in MOR null neuropathic mice. Biochemical analyses highlight a significant increase in beta-endorphin levels by 30% in the brain of lithium-treated mice compared to controls. No variation of beta-endorphin was detected in the blood. Conclusions Together, our results provide evidence that lithium induces a long-lasting analgesia in neuropathic mice presumably through elevated brain levels of beta-endorphin and the activation of MORs.


Subject(s)
Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Lithium/therapeutic use , Receptors, Opioid, mu/metabolism , Analgesia , Animals , Biogenic Monoamines/blood , Catecholamines/blood , Disease Models, Animal , Hyperalgesia/blood , Limit of Detection , Lithium/pharmacology , Male , Mice, Inbred C57BL , Neuralgia/blood , Neuralgia/drug therapy , Neuralgia/pathology , Nociception/drug effects , Receptors, Opioid, mu/deficiency
6.
Int J Neuropsychopharmacol ; 20(5): 403-409, 2017 05 01.
Article in English | MEDLINE | ID: mdl-28031268

ABSTRACT

Background: Opioid and dopamine systems play crucial roles in reward. Similarities and differences in the neural mechanisms of reward that are mediated by these 2 systems have remained largely unknown. Thus, in the present study, we investigated the differences in reward function in both µ-opioid receptor knockout mice and dopamine transporter knockout mice, important molecules in the opioid and dopamine systems. Methods: Mice were implanted with electrodes into the right lateral hypothalamus (l hour). Mice were then trained to put their muzzle into the hole in the head-dipping chamber for intracranial electrical stimulation, and the influences of gene knockout were assessed. Results: Significant differences are observed between opioid and dopamine systems in reward function. µ-Opioid receptor knockout mice exhibited enhanced intracranial electrical stimulation, which induced dopamine release. They also exhibited greater motility under conditions of "despair" in both the tail suspension test and water wheel test. In contrast, dopamine transporter knockout mice maintained intracranial electrical stimulation responding even when more active efforts were required to obtain the reward. Conclusions: The absence of µ-opioid receptor or dopamine transporter did not lead to the absence of intracranial electrical stimulation responsiveness but rather differentially altered it. The present results in µ-opioid receptor knockout mice are consistent with the suppressive involvement of µ-opioid receptors in both positive incentive motivation associated with intracranial electrical stimulation and negative incentive motivation associated with depressive states. In contrast, the results in dopamine transporter knockout mice are consistent with the involvement of dopamine transporters in positive incentive motivation, especially its persistence. Differences in intracranial electrical stimulation in µ-opioid receptor and dopamine transporter knockout mice underscore the multidimensional nature of reward.


Subject(s)
Analgesics, Opioid/metabolism , Dopamine/metabolism , Hypothalamic Area, Lateral/drug effects , Hypothalamic Area, Lateral/metabolism , Receptors, Opioid, mu/deficiency , Animals , Biophysics , Dopamine Plasma Membrane Transport Proteins/deficiency , Dopamine Plasma Membrane Transport Proteins/genetics , Electric Stimulation , Mice , Mice, Inbred C57BL , Mice, Knockout , Motivation , Motor Activity/drug effects , Receptors, Opioid, mu/genetics , Reward , Self Administration , Time Factors
8.
Neural Plast ; 2016: 5346161, 2016.
Article in English | MEDLINE | ID: mdl-27274875

ABSTRACT

Environmental enrichment has been proven to have positive effects on both behavioral and physiological phenotypes in rodent models of mental and neurodevelopmental disorders. In this study, we used mice lacking the µ-opioid receptor gene (Oprm1 (-/-)), which has been shown to have deficits in social competence and communication, to assess the hypothesis that early enrichment can ameliorate sociability during development and adulthood. Due to the immaturity of sensory-motor capabilities of young pups, we chose as environmental stimulation a second lactating female, who provided extra maternal care and stimulation from birth. The results show that double mothering normalized the abnormal response to maternal separation in Oprm1 (-/-) pups and increased social motivation in juveniles and adult knockout mice. Additionally, we observed that Oprm1 (-/-) mice act as less attractive social partners than wild types, which suggests that social motivation can be modulated by the stimulus employed. This experiment supports previous findings suggesting that early social environmental stimulation has profound and long-term beneficial effects, encouraging the use of nonpharmacological interventions for the treatment of social defects in neurodevelopmental diseases.


Subject(s)
Autistic Disorder/metabolism , Disease Models, Animal , Environment , Motivation/physiology , Receptors, Opioid, mu/deficiency , Social Behavior , Animals , Autistic Disorder/genetics , Avoidance Learning/physiology , Female , Male , Maternal Deprivation , Mice , Mice, Knockout , Receptors, Opioid, mu/genetics
9.
Am J Pathol ; 184(4): 1073-1084, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24495739

ABSTRACT

Tumor cells secrete factors that stimulate the migration of peripheral blood leukocytes and enhance tumor progression by affecting angiogenesis. In these studies, we investigated the effect of morphine, a known immunosuppressant, on leukocyte migration and recruitment to conditioned media derived from long-term cultures of mouse Lewis lung carcinoma cells. Our results indicate that morphine treatment reduced the migration and recruitment of tumor-infiltrating leukocytes into Matrigel plugs and polyvinyl alcohol sponges containing conditioned media derived from long-term cultures of mouse Lewis lung carcinoma cells when compared with placebo. A reciprocal increase in peripheral blood leukocytes was observed at the time of plug or sponge removal in morphine-treated mice. Decreased angiogenesis was observed in conditioned media derived from long-term cultures of mouse Lewis lung carcinoma cells Matrigel plugs taken from morphine-treated wild-type mice when compared with placebo but was abolished in morphine-treated µ-opioid receptor knockout mice. In addition, in vitro studies using trans-well and electric cell substrate impedance sensing system studies reveal for the first time morphine's inhibitory effects on leukocyte migration and their ability to transmigrate across an activated endothelial monolayer. Taken together, these studies indicate that morphine treatment can potentially decrease leukocyte transendothelial migration and reduce angiogenesis associated with tumor growth. The use of morphine for cancer pain management may be beneficial through its effects on angiogenesis.


Subject(s)
Carcinoma, Lewis Lung/pathology , Immunosuppressive Agents/pharmacology , Lymphocytes, Tumor-Infiltrating/drug effects , Morphine/pharmacology , Neovascularization, Pathologic/pathology , Transendothelial and Transepithelial Migration/drug effects , Animals , Cell Line, Tumor , Culture Media, Conditioned/pharmacology , Female , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics
10.
Addict Biol ; 19(5): 770-80, 2014 Sep.
Article in English | MEDLINE | ID: mdl-23461397

ABSTRACT

Ethanol exposure and withdrawal alter the generation of new neurons in the adult hippocampus. The endogenous opioid system, particularly the µ-opioid receptor (MOR), can modulate neural progenitors and also plays a critical role in ethanol drinking and dependence. In the present study, we sought to determine whether MOR contributes to the effects of ethanol on the dentate gyrus (DG) neurogenic niche. MOR wild-type (WT), heterozygous (Het) and knockout (KO) littermates were subjected to voluntary ethanol drinking in repeated limited-access two-bottle choice (2BC) sessions. MOR deficiency did not alter progenitor proliferation, neuronal differentiation and maturation, apoptosis or microglia in ethanol-naïve mice. When exposed to five consecutive weeks of 2BC, MOR mutant mice exhibited a gene-dosage-dependent reduction of ethanol consumption compared with WT mice. Introducing a week of ethanol deprivation between each week of 2BC increased ethanol consumption in all genotypes and produced equivalent intakes in WT, Het and KO mice. Under the latter paradigm, ethanol drinking decreased progenitor proliferation and neuronal differentiation in the DG of WT mice. Interestingly, WT mice exhibited a strong negative correlation between ethanol intake and proliferation, which was disrupted in Het and KO mice. Moreover, MOR deficiency blocked the effect of ethanol on neuronal differentiation. MOR deficiency also protected against the neuroimmune response to ethanol drinking. Finally, chronic binge drinking induced a paradoxical decrease in apoptosis, which was independent of MOR. Altogether, our data suggest that MOR is implicated in some of the neuroplastic changes produced by chronic ethanol exposure in the DG.


Subject(s)
Binge Drinking/physiopathology , Hippocampus/drug effects , Receptors, Opioid, mu/physiology , Analysis of Variance , Animals , Antimetabolites/pharmacology , Bromodeoxyuridine/pharmacology , Cell Differentiation/drug effects , Cell Proliferation/drug effects , Doublecortin Protein , Hippocampus/cytology , Male , Mice, Inbred C57BL , Mice, Knockout , Neuroimmunomodulation/drug effects , Neurons/drug effects , Neurons/metabolism , Receptors, Opioid, mu/deficiency , Self Administration , Signal Transduction/drug effects
11.
Int J Neuropsychopharmacol ; 16(1): 151-62, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22217458

ABSTRACT

Most classical preclinical tests to predict antidepressant activity were initially developed to detect compounds that influenced noradrenergic and/or serotonergic activity, in accordance with the monoaminergic hypothesis of depression. However, central opioid systems are also known to influence the pathophysiology of depression. While the tail suspension test (TST) is very sensitive to several types of antidepressant, the traditional form of scoring the TST does not distinguish between different modes of action. The present study was designed to compare the behavioural effects of classical noradrenergic and/or serotonergic antidepressants in the TST with those of opioids. We developed a sampling technique to differentiate between behaviours in the TST, namely, curling, swinging and immobility. Antidepressants that inhibit noradrenaline and/or serotonin re-uptake (imipramine, venlafaxine, duloxetine, desipramine and citalopram) decreased the immobility of mice, increasing their swinging but with no effect on their curling behaviour. No differences were observed between antidepressants that act on noradrenergic or serotoninergic transmission. While opioid compounds also decreased the immobility of the mice [morphine, codeine, levorphanol, (-)-methadone, (±)-tramadol and (+)-tramadol], they selectively increased curling behaviour. Blocking opioid receptors with naloxone prevented the antidepressant-like effect of codeine, and µ-opioid receptor knockout decreased normal curling behaviour and blocked (±)-tramadol-induced curling, further demonstrating the reliability and validity of this approach. These results show that at least two behaviourally distinct processes occur in the TST, highlighting the antidepressant-like effects of opioids evident in this test. Furthermore, our data suggest that swinging and curling behaviours are mediated by enhanced monoamine and opioid neurotransmission, respectively.


Subject(s)
Analgesics, Opioid/pharmacology , Antidepressive Agents/pharmacology , Hindlimb Suspension/physiology , Motor Activity/physiology , Animals , Female , Hindlimb Suspension/methods , Hindlimb Suspension/psychology , Immobility Response, Tonic/drug effects , Immobility Response, Tonic/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/drug effects , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics
12.
Nat Genet ; 25(2): 195-200, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10835636

ABSTRACT

The role of the opioid system in controlling pain, reward and addiction is well established, but its role in regulating other emotional responses is poorly documented in pharmacology. The mu-, delta- and kappa- opioid receptors (encoded by Oprm, Oprd1 and Oprk1, respectively) mediate the biological activity of opioids. We have generated Oprd1-deficient mice and compared the behavioural responses of mice lacking Oprd1, Oprm (ref. 6) and Oprk1 (ref. 7) in several models of anxiety and depression. Our data show no detectable phenotype in Oprk1-/- mutants, suggesting that kappa-receptors do not have a role in this aspect of opioid function; opposing phenotypes in Oprm-/- and Oprd1-/- mutants which contrasts with the classical notion of similar activities of mu- and delta-receptors; and consistent anxiogenic- and depressive-like responses in Oprd1-/- mice, indicating that delta-receptor activity contributes to improvement of mood states. We conclude that the Oprd1-encoded receptor, which has been proposed to be a promising target for the clinical management of pain, should also be considered in the treatment of drug addiction and other mood-related disorders.


Subject(s)
Anxiety/metabolism , Depression/metabolism , Gene Deletion , Receptors, Opioid, delta/metabolism , Receptors, Opioid, mu/metabolism , Animals , Anxiety/genetics , Binding Sites , Darkness , Depression/genetics , Electroshock , Female , Light , Male , Mice , Mice, Knockout , Motor Activity/drug effects , Naloxone/pharmacology , Naltrexone/analogs & derivatives , Naltrexone/metabolism , Naltrexone/pharmacology , Narcotic Antagonists/metabolism , Narcotic Antagonists/pharmacology , Pain Threshold/drug effects , Phenotype , Receptors, Opioid, delta/deficiency , Receptors, Opioid, delta/genetics , Receptors, Opioid, kappa/deficiency , Receptors, Opioid, kappa/genetics , Receptors, Opioid, kappa/metabolism , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics , Sex Characteristics , Swimming
13.
J Neurosci ; 31(42): 14861-70, 2011 Oct 19.
Article in English | MEDLINE | ID: mdl-22016519

ABSTRACT

µ-Opioid receptors (µORs) are selectively expressed on interneurons in area CA1 of the hippocampus. Fast-spiking, parvalbumin-expressing, basket cells express µORs, but circumstantial evidence suggests that another major, unidentified, GABAergic cell class must also be modulated by µORs. Here we report that the abundant, dendritically targeting, neurogliaform family of cells (Ivy and neurogliaform cells) is a previously unrecognized target of direct modulation by µORs. Ivy and neurogliaform cells are not only numerous but also have unique properties, including promiscuous gap junctions formed with various interneuronal subtypes, volume transmission, and the ability to produce a postsynaptic GABA(B) response after a single presynaptic spike. Using a mouse line expressing green fluorescent protein under the neuropeptide Y promoter, we find that, across all layers of CA1, activation of µORs hyperpolarizes Ivy and neurogliaform cells. Furthermore, paired recordings between synaptically coupled Ivy and pyramidal cells show that Ivy cell terminals are dramatically inhibited by µOR activation. Effects in Ivy and neurogliaform cells are seen at similar concentrations of agonist as those producing inhibition in fast-spiking parvalbumin basket cells. We also report that Ivy cells display the recently described phenomenon of persistent firing, a state of continued firing in the absence of continued input, and that induction of persistent firing is inhibited by µOR activation. Together, these findings identify a major, previously unrecognized, target of µOR modulation. Given the prominence of this cell type in and beyond CA1, as well as its unique role in microcircuitry, opioid modulation of neurogliaform cells has wide implications.


Subject(s)
Interneurons/classification , Interneurons/physiology , Receptors, Opioid, mu/metabolism , Action Potentials/drug effects , Action Potentials/physiology , Analgesics, Opioid/pharmacology , Analysis of Variance , Animals , Animals, Newborn , Biophysics , Cell Adhesion Molecules, Neuronal/metabolism , Dose-Response Relationship, Drug , Electric Stimulation , Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology , Extracellular Matrix Proteins/metabolism , Gene Expression Regulation/drug effects , Gene Expression Regulation/genetics , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Hippocampus/cytology , In Vitro Techniques , Interneurons/cytology , Mice , Mice, Transgenic , Narcotic Antagonists/pharmacology , Nerve Tissue Proteins/metabolism , Neuropeptide Y/genetics , Nitric Oxide Synthase Type III/metabolism , Parvalbumins/metabolism , Patch-Clamp Techniques/methods , Peptides/pharmacology , Plant Lectins/metabolism , Rats , Rats, Wistar , Receptors, Opioid, mu/deficiency , Reelin Protein , Serine Endopeptidases/metabolism , Statistics, Nonparametric , Synaptic Potentials/drug effects , Synaptic Potentials/genetics
14.
Exp Dermatol ; 20(1): 24-8, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20955200

ABSTRACT

Opioids exert major effects not only in the central nervous system but also in immune responses. We investigated the effects of µ-opioid peptides, secreted by tumor cells, on anti-tumor immune responses. For this purpose, tumor growth was studied in wild-type and µ-opioid receptor-deficient (MOR-/-) mice injected with B16 melanoma cells. The ability of these cells to produce opioids was studied by Western blots in vitro. Finally, biopsy material from human melanomas was investigated by immunohistochemistry for ß endorphin expression. Injection of B16 melanoma cells, producing endogenous ß endorphin, in the flank of MOR-/- mice revealed a profound reduction in tumor growth, paralleled by a significantly higher infiltration of immune cells into the tumors, when compared to tumor growth after injection of B16 melanoma cells into wild-type mice. Opioids present in B16 cell supernatant significantly reduced the proliferation of normal but not MOR-/- leucocytes. Immunohistochemical analyses of biopsies from human melanoma tissues showed a positive correlation between expression of ß endorphin and tumor progression. Our data provide evidence that µ-opioid peptides may play a major role in cancer progression by modulating immune response. This finding may have implications for the future optimization of immunointerventions for cancer.


Subject(s)
Melanoma/immunology , Opioid Peptides/immunology , Skin Neoplasms/immunology , Animals , Disease Progression , Humans , Lymphocytes, Tumor-Infiltrating/drug effects , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/pathology , Melanoma/metabolism , Melanoma/pathology , Melanoma, Experimental/immunology , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Mice, Knockout , Opioid Peptides/biosynthesis , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/immunology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , beta-Endorphin/immunology , beta-Endorphin/metabolism
15.
CNS Neurosci Ther ; 27(7): 831-841, 2021 07.
Article in English | MEDLINE | ID: mdl-34018697

ABSTRACT

AIMS: Naltrexone is a mu opioid receptor (MOR) antagonist used to treat drug dependence in patients. Previous reports indicated that MOR antagonists reduced neurodegeneration and inflammation after brain injury. The purpose of this study was to evaluate the neuroprotective effect of naltrexone in cell culture and a mouse model of traumatic brain injury (TBI). METHODS: The neuroprotective effect of naltrexone was examined in primary cortical neurons co-cultured with BV2 microglia. Controlled cortical impact (CCI) was delivered to the left cerebral cortex of adult male MOR wild-type (WT) and knockout (KO) mice. Naltrexone was given daily for 4 days, starting from day 2 after lesioning. Locomotor activity was evaluated on day 5 after the CCI. Brain tissues were collected for immunostaining, Western, and qPCR analysis. RESULTS: Glutamate reduced MAP2 immunoreactivity (-ir), while increased IBA1-ir in neuron/BV2 co-culture; both responses were antagonized by naltrexone. TBI significantly reduced locomotor activity and increased the expression of IBA1, iNOS, and CD4 in the lesioned cortex. Naltrexone significantly and equally antagonized the motor deficits and expression of IBA1 and iNOS in WT and KO mice. TBI-mediated CD4 protein production was attenuated by naltrexone in WT mice, but not in KO mice. CONCLUSION: Naltrexone reduced TBI-mediated neurodegeneration and inflammation in MOR WT and KO mice. The protective effect of naltrexone involves non-MOR and MOR mechanisms.


Subject(s)
Brain Injuries, Traumatic/metabolism , Brain Injuries, Traumatic/prevention & control , Naltrexone/therapeutic use , Narcotic Antagonists/therapeutic use , Neuroprotective Agents/therapeutic use , Receptors, Opioid, mu/deficiency , Animals , Coculture Techniques , Male , Mice , Mice, Knockout , Mice, Transgenic , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Neuroprotective Agents/pharmacology , Receptors, Opioid, mu/antagonists & inhibitors , Receptors, Opioid, mu/genetics
16.
J Neurosci ; 29(22): 7341-8, 2009 Jun 03.
Article in English | MEDLINE | ID: mdl-19494155

ABSTRACT

Buprenorphine is a weak partial agonist at mu-opioid receptors that is used for treatment of pain and addiction. Intracellular and whole-cell recordings were made from locus ceruleus neurons in rat brain slices to characterize the actions of buprenorphine. Acute application of buprenorphine caused a hyperpolarization that was prevented by previous treatment of slices with the irreversible opioid antagonist beta-chlornaltrexamine (beta-CNA) but was not reversed by a saturating concentration of naloxone. As expected for a partial agonist, subsaturating concentrations of buprenorphine decreased the [Met](5)enkephalin (ME)-induced hyperpolarization or outward current. When the ME-induced current was decreased below a critical value, desensitization and internalization of mu-opioid receptors was eliminated. The inhibition of desensitization by buprenorphine was not the result of previous desensitization, slow dissociation from the receptor, or elimination of receptor reserve. Treatment of slices with subsaturating concentrations of etorphine, methadone, oxymorphone, or beta-CNA also reduced the current induced by ME but did not block ME-induced desensitization. Treatment of animals with buprenorphine for 1 week resulted in the inhibition of the current induced by ME and a block of desensitization that was not different from the acute application of buprenorphine to brain slices. These observations show the unique characteristics of buprenorphine and further demonstrate the range of agonist-selective actions that are possible through G-protein-coupled receptors.


Subject(s)
Buprenorphine/pharmacology , Narcotics/pharmacology , Neural Inhibition/drug effects , Neurons/drug effects , Receptors, Opioid, mu/metabolism , Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Analysis of Variance , Animals , Biophysics , Brain/cytology , Brain/drug effects , Brimonidine Tartrate , Dose-Response Relationship, Drug , Electric Stimulation/methods , Enkephalin, Methionine/pharmacology , In Vitro Techniques , Male , Membrane Potentials/drug effects , Membrane Potentials/genetics , Mice , Mice, Transgenic , Naltrexone/analogs & derivatives , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Neural Inhibition/genetics , Neurons/physiology , Patch-Clamp Techniques/methods , Quinoxalines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/agonists , Receptors, Opioid, mu/deficiency , Yohimbine/pharmacology
17.
Biochim Biophys Acta ; 1793(8): 1366-71, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19477204

ABSTRACT

The mechanisms by which opioids affect progression of human immunodeficiency virus type 1 (HIV-1) infection are not well-defined. HIV-1 gp120 is important in the apoptotic death of uninfected, bystander T cells. In this study, we show that co-treatment of human peripheral blood mononuclear cells (PBMC) with HIV-1 gp120/morphine synergistically induces apoptosis in PBMC. Co-treatment of murine splenocytes from mu opiate receptor knockout mice with gp120/morphine resulted in decreased apoptosis when compared to splenocytes from wild type mice. Co-treatment of human PBMC or murine splenocytes with gp120/morphine led to decreased expression of beta-arrestin 2, a protein required for opioid-mediated signaling. The role of beta-arrestin 2 was confirmed in Jurkat lymphocytes, in which 1) over-expression of beta-arrestin 2 inhibited gp120/morphine-induced apoptosis and 2) RNA interference of beta-arrestin 2 expression enhanced gp120/morphine-induced apoptosis. These data suggest a novel mechanism by which HIV-1 gp120 and opioids induce lymphocyte cell death.


Subject(s)
Apoptosis/drug effects , Apoptosis/physiology , Arrestins/physiology , HIV Envelope Protein gp120/physiology , HIV-1/physiology , Lymphocytes/drug effects , Lymphocytes/virology , Morphine/pharmacology , Analgesics, Opioid/pharmacology , Animals , Arrestins/antagonists & inhibitors , Arrestins/genetics , HIV Envelope Protein gp120/genetics , HIV-1/genetics , HIV-1/pathogenicity , Humans , In Vitro Techniques , Jurkat Cells , Lymphocytes/pathology , Lymphocytes/physiology , Mice , Mice, Knockout , RNA Interference , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics , beta-Arrestin 2 , beta-Arrestins
18.
J Exp Med ; 185(8): 1517-22, 1997 Apr 21.
Article in English | MEDLINE | ID: mdl-9126934

ABSTRACT

The mu opioid receptor is thought to be the cellular target of opioid narcotics such as morphine and heroin, mediating their effects in both pain relief and euphoria. Its involvement is also implicated in a range of diverse biological processes. Using a mouse model in which the receptor gene was disrupted by targeted homologous recombination, we explored the involvement of this receptor in a number of physiological functions. Mice homozygous for the disrupted gene developed normally, but their motor function was altered. Drug-naive homozygotes displayed reduced locomotor activity, and morphine did not induce changes in locomotor activity observed in wild-type mice. Unexpectedly, lack of a functional receptor resulted in changes in both the host defense system and the reproductive system. We observed increased proliferation of granulocyte-macrophage, erythroid, and multipotential progenitor cells in both bone marrow and spleen, indicating a link between hematopoiesis and the opioid system, both of which are stress-responsive systems. Unexpected changes in sexual function in male homozygotes were also observed, as shown by reduced mating activity, a decrease in sperm count and motility, and smaller litter size. Taken together, these results suggest a novel role of the mu opioid receptor in hematopoiesis and reproductive physiology, in addition to its known involvement in pain relief.


Subject(s)
Behavior, Animal/physiology , Hematopoiesis , Receptors, Opioid, mu/deficiency , Animals , Female , Male , Mice , Mice, Knockout , Motor Activity/physiology , Sexual Behavior, Animal/physiology , Sperm Motility
19.
J Neurosci Res ; 88(10): 2294-302, 2010 Aug 01.
Article in English | MEDLINE | ID: mdl-20209629

ABSTRACT

Repeated administration of psychostimulants to rodents can lead to behavioral sensitization. Previous studies, using nonspecific opioid receptor (OR) antagonists, revealed that ORs were involved in modulation of behavioral sensitization to methamphetamine (METH). However, the contribution of OR subtypes remains unclear. In the present study, using mu-OR knockout mice, we examined the role of mu-OR in the development of METH sensitization. Mice received daily intraperitoneal injection of drug or saline for 7 consecutive days to initiate sensitization. To express sensitization, animals received one injection of drug (the same as for initiation) or saline on day 11. Animal locomotor activity and stereotypy were monitored during the periods of initiation and expression of sensitization. Also, the concentrations of METH and its active metabolite amphetamine in the blood were measured after single and repeated administrations of METH. METH promoted significant locomotor hyperactivity at low doses and stereotyped behaviors at relative high doses (2.5 mg/kg and above). Repeated administration of METH led to the initiation and expression of behavioral sensitization in wild-type mice. METH-induced behavioral responses were attenuated in the mu-OR knockout mice. Haloperidol (a dopamine receptor antagonist) showed a more potent effect in counteracting METH-induced stereotypy in the mu-OR knockout mice. Saline did not induce behavioral sensitization in either genotype. No significant difference was observed in disposition of METH and amphetamine between the two genotypes. Our study indicated that the mu-opioid system is involved in modulating the development of behavioral sensitization to METH. (c) 2010 Wiley-Liss, Inc.


Subject(s)
Akathisia, Drug-Induced/metabolism , Central Nervous System Stimulants/pharmacology , Methamphetamine/pharmacology , Receptors, Opioid, mu/metabolism , Akathisia, Drug-Induced/blood , Akathisia, Drug-Induced/drug therapy , Amphetamine/blood , Animals , Central Nervous System Stimulants/administration & dosage , Central Nervous System Stimulants/blood , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Methamphetamine/administration & dosage , Methamphetamine/blood , Mice , Mice, Inbred C57BL , Mice, Knockout , Motor Activity/drug effects , Receptors, Opioid, mu/deficiency , Receptors, Opioid, mu/genetics , Stereotyped Behavior/drug effects
20.
Microb Pathog ; 49(6): 330-5, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20688146

ABSTRACT

Previous studies from our laboratory demonstrated that mice treated with morphine pellets are sensitized to Salmonella enterica, serovar Typhimurium infection. However, the opioid receptor antagonist, naltrexone, only partially blocked the effect of morphine, raising the possibility that the opioid might have some of its effects through a nonopioid receptor. To further clarify whether sensitization to infection is an opioid receptor-dependent phenomenon, µ-opioid receptor knockout (MORKO) mice were used in the present study. Wild-type (WT) and MORKO mice were treated with morphine and their sensitivity to oral Salmonella infection was assessed by mortality, bacterial burdens in gut associated lymphoid tissue and in blood and peritoneal fluid, and by levels of pro-inflammatory cytokines in plasma. MORKO animals treated with morphine were refractory to a sublethal dose of Salmonella, while similar treatment of WT animals resulted in 100% mortality. WT animals treated with morphine had high bacterial loads in all organs tested, while morphine-treated MORKO animals had no culturable Salmonella in any organs. Pro-inflammatory cytokine levels were elevated in morphine-treated WT but not MORKO mice infected with Salmonella. These results provide definitive evidence that the morphine-mediated enhancement of oral Salmonella infection is dependent on the µ-opioid receptor.


Subject(s)
Disease Susceptibility/chemically induced , Morphine/toxicity , Receptors, Opioid, mu/drug effects , Salmonella Infections, Animal/microbiology , Salmonella typhimurium/pathogenicity , Animals , Ascitic Fluid/microbiology , Bacterial Load , Blood/microbiology , Cytokines/blood , Disease Models, Animal , Female , Lymphoid Tissue/microbiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptors, Opioid, mu/deficiency , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL